Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

Korean Red Ginseng slows coreceptor switch in HIV-1 infected patients

  • Young-Keol, Cho (Departments of Microbiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jung-Eun, Kim (Departments of Microbiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jinny, Lee (Departments of Microbiology, University of Ulsan College of Medicine, Asan Medical Center)
  • Received : 2022.05.23
  • Accepted : 2022.06.29
  • Published : 2023.01.02
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Human immunodeficiency virus-1 (HIV-1) that binds to the coreceptor CCR5 (R5 viruses) can evolve into viruses that bind to the coreceptor CXCR4 (X4 viruses), with high viral replication rates governing this coreceptor switch. Korean Red Ginseng (KRG) treatment of HIV-1 infected patients has been found to slow the depletion of CD4+ T cells. This study assessed whether the KRG-associated slow depletion of CD4+ T cells was associated with coreceptor switching. Methods: This study included 146 HIV-1-infected patients naïve to antiretroviral therapy (ART) and seven patients receiving ART. A total of 540 blood samples were obtained from these patients over 122 ± 129 months. Their env genes were amplified by nested PCR or RT-PCR and subjected to direct sequencing. Tropism was determined with a 10% false positive rate (FPR) cutoff. Results: Of the 146 patients naïve to ART, 102 were KRG-naïve, and 44 had been treated with KRG. Evaluation of initial samples showed that coreceptor switch had occurred in 19 patients, later occurring in 38 additional patients. There was a significant correlation between the amount of KRG and FPR. Based on initial samples, the R5 maintenance period was extended 2.35-fold, with the coreceptor switch being delayed 2.42-fold in KRG-treated compared with KRG-naïve patients. The coreceptor switch occurred in 85% of a homogeneous cohort. The proportion of patients who maintained R5 for ≥10 years was significantly higher in long-term slow progressors than in typical progressors. Conclusion: KRG therapy extends R5 maintenance period by increasing FPR, thereby slowing the coreceptor switch.

Keywords

Acknowledgement

This study was supported by a grant from the Korean Society of Ginseng, Republic of Korea (2020).

References

  1. Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS 1997;11(Suppl A):S3-16.
  2. Mild M, Kvist A, Esbjornsson J, Karlsson I, Fenyo EM, Medstrand P. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and nonswitch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol 2010;10:356-64. https://doi.org/10.1016/j.meegid.2009.05.003
  3. Mild M, Gray RR, Kvist A, Lemey P, Goodenow MM, Fenyo EM, Albert J, Salemi M, Esbjornsson J, Medstrand P. High intrapatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch. Infect Genet Evol 2013;19:369-77. https://doi.org/10.1016/j.meegid.2013.05.004
  4. Nedellec R, Herbeck JT, Hunt PW, Deeks SG, Mullins JI, Anton ED, Reeves JD, Mosier DE. High-sequence diversity and rapid virus turnover contribute to higher rates of coreceptor switching in treatment-experienced subjects with HIV-1 viremia. AIDS Res Hum Retroviruses 2017;33:234-45. https://doi.org/10.1089/aid.2016.0153
  5. Connell BJ, Hermans LE, Wensing AMJ, Schellens I, Schipper PJ, van Ham PM, de Jong DTCM, Otto S, Mathe T, Moraba R, et al. Immune activation correlates with and predicts CXCR4 co-receptor tropism switch in HIV-1 infection. Sci Rep 2020;10:15866. https://doi.org/10.1038/s41598-020-71699-z
  6. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 2005;13:269-77. https://doi.org/10.1016/j.tim.2005.04.005
  7. Santoro MM, Armenia D, Fabeni L, Santoro M, Gori C, Forbici F, Svicher V, Bertoli A, Dori L, Surdo M, et al. The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. Clin Microbiol Infect 2012;18:E289-98. https://doi.org/10.1111/j.1469-0691.2012.03905.x
  8. Arif MS, Hunter J, Leda AR, Zukurov JPL, Samer S, Camargo M, Galinskas J, Kall as EG, Komninakis SV, Janini LM, et al. Pace of coreceptor tropism switch in HIV-1-infected individuals after recent infection. J Virol 2017;91:-00793- 17. https://doi.org/10.1128/JVI.00793-17
  9. Sung H, Kang SM, Lee MS, Kim TG, Cho YK. Korean red ginseng slows depletion of CD4 T cells in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 2005;12:497-501. https://doi.org/10.1128/CDLI.12.4.497-501.2005
  10. Cho YK, Kim JE, Woo JH. Genetic defects in the nef gene are associated with Korean Red Ginseng intake: monitoring of nef sequence polymorphisms over 20 years. J Ginseng Res 2017;41:144-50. https://doi.org/10.1016/j.jgr.2016.02.005
  11. Cho YK, Kim JE. Effect of Korean Red Ginseng intake on the survival duration of human immunodeficiency virus type 1 patients. J Ginseng Res 2017;41: 222-6. https://doi.org/10.1016/j.jgr.2016.12.006
  12. Cho YK, Sung HS. Effect of Korean Red Ginseng on serum soluble CD8 in HIV1-infected patients. J Ginseng Res 2007;31:175-80. https://doi.org/10.5142/JGR.2007.31.4.175
  13. Cho YK, Lim JY, Jung YS, Oh SK, Lee HJ, Sung H. High frequency of grossly deleted nef genes in HIV-1 infected long-term slow progressors treated with Korean red ginseng. Current HIV Res 2006;4:447-57. https://doi.org/10.2174/157016206778560072
  14. Cho YK, Jung YS. High frequency of gross deletions in the 5' LTR and gag regions in HIV type 1-infected long-term survivors treated with Korean red ginseng. AIDS Res Hum Retroviruses 2008;24:181-93. https://doi.org/10.1089/aid.2007.0143
  15. Cho YK, Jung YS. Dosage and duration effects of Korean red ginseng intake on frequency of gross deletions in the nef gene. J Ginseng Res 2010;34:219-25. https://doi.org/10.5142/jgr.2010.34.3.219
  16. Cho YK, Jung YS, Sung H. Frequent gross deletion in the HIV type 1 nef gene in hemophiliacs treated with Korean red ginseng: inhibition of detection by highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2009;25: 419-24. https://doi.org/10.1089/aid.2008.0178
  17. Cho YK, Jung Y, Sung H, Joo CH. Frequent genetic defects in the HIV-1 5'LTR/ gag gene in hemophiliacs treated with Korean red ginseng: decreased detection of genetic defects by highly active antiretroviral therapy. J Ginseng Res 2011;35:413-20. https://doi.org/10.5142/jgr.2011.35.4.413
  18. Cho YK, Kim JE, Woo JH. Korean Red Ginseng increases defective pol gene in peripheral blood mononuclear cells of HIV-1-infected patients; inhibition of its detection during ginseng-based combination therapy. J Ginseng Res 2019;43:684-91. https://doi.org/10.1016/j.jgr.2019.05.011
  19. Cho YK, Foley BT, Sung H, Kim YB, Kim JH. Molecular epidemiologic study of a human immunodeficiency virus 1 outbreak in haemophiliacs B infected through clotting factor 9 after 1990. Vox Sang 2007;92:113-20. https://doi.org/10.1111/j.1423-0410.2006.00866.x
  20. Cho YK, Jung YS, Foley BT. Phylogenetic analysis of full-length pol gene from Korean hemophiliacs and plasma donors infected with Korean subclade B of HIV type 1. AIDS Res Hum Retroviruses 2011;27:613-21. https://doi.org/10.1089/aid.2010.0174
  21. Cho YK, Kim JE, Jeong D, Foley BT. Signature pattern analysis for the fulllength env gene of the earliest Korean subclade B of HIV-1: outbreak among Korean hemophiliacs. Virus Genes 2017;53:789-96. https://doi.org/10.1007/s11262-017-1477-4
  22. Cho YK, Kim JE, Foley BT. Sequence length of HIV-1 subtype B increases over time: analysis of a cohort of patients with hemophilia over 30 years. Viruses 2021;13:806. https://doi.org/10.3390/v13050806
  23. Cho YK, Lee HJ, Kim YB, Oh WI, Kim YK. Sequence analysis of C2-V3 region of human immunodeficiency virus type 1 gp120 and its correlation with clinical significance: the effect of long-term intake of Korean Red Ginseng on env gene variation. J Korean Soc Microbiol 1997;32:611-23.
  24. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vezinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, et al. European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11: 394-407. https://doi.org/10.1016/S1473-3099(10)70319-4
  25. Poveda E, Paredes R, Moreno S, Alcami J, Cordoba J, Delgado R, Guti errez F, Llibre JM, Garcia Deltoro M, Hern andez-Quero J, et al. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. AIDS Rev 2012;14:208-17.
  26. Cho YK, Kim YB, Choi BS, Kim YK, Choi MH, Jang YS, Shin YO. Effect of Korean red ginseng on the levels of serum p24 antigen, ß2-microglobulin, and CD4+ T cell counts in HIV infected patients treated with AZT (I). Korean J Microbiol 1993;28:409-17.
  27. Cho YK, Kim YK, Lee I, Choi MH, Shin YO. The effect of Korean Red Ginseng (KRG), zidovudine (ZDV), and the combination of KRG and ZDV on HIVinfected individuals. Korean J Microbiol 1996;28:409-17.
  28. Cho YK, Kim BR, Kim JE, Woo JH, Foley BT. First report on a T69-ins insertion in CRF06_cpx HIV type 1. AIDS Res Hum Retroviruses 2013;29:1079-84. https://doi.org/10.1089/AID.2013.0013
  29. Song JH, Choi HJ, Song HH, Hong EH, Lee BR, Oh SR, Choi K, Yeo SG, Lee YP, Cho S, et al. Antiviral activity of ginsenosides against coxsackievirus B3, enterovirus 71, and human rhinovirus 3. J Ginseng Res 2014;38:173-9. https://doi.org/10.1016/j.jgr.2014.04.003
  30. Kang N, Gao H, He L, Liu Y, Fan H, Xu Q, Yang S. Ginsenoside Rb1 is an immune-stimulatory agent with antiviral activity against enterovirus 71. J Ethnopharmacol 2021;266:113401. https://doi.org/10.1016/j.jep.2020.113401
  31. Ratan ZA, Haidere MF, Hong YH, Park SH, Lee JO, Lee J, Cho JY. Pharmacological potential of ginseng and its major component ginsenosides. J Ginseng Res 2021;45:199-210. https://doi.org/10.1016/j.jgr.2020.02.004
  32. O'Connell RJ, Merritt TM, Malia JA, VanCott TC, Dolan MJ, Zahwa H, Bradley WP, Branson BM, Michael NL, De Witt CC. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol 2003;41:2153-5. https://doi.org/10.1128/JCM.41.5.2153-2155.2003
  33. Son YM, Kwak CW, Lee YJ, Yang DC, Park BC, Lee WK, Han SH, Yun CH. Ginsenoside Re enhances survival of human CD4+ T cells through regulation of autophagy. Int Immunopharmacol 2010;10:626-31. https://doi.org/10.1016/j.intimp.2010.03.002
  34. Tan B, Giangaspero M, Sun N, Jin Y, Liu K, Wang Q, Cheng S, Wang Y, Zhang S. Antiviral effect of Ginsenoside Rb2 and Rb3 against bovine viral diarrhea virus and classical swine fever virus in vitro. Front Vet Sci 2021;8:764909. https://doi.org/10.3389/fvets.2021.764909
  35. Xu HL, Chen GH, Wu YT, Xie LP, Tan ZB, Liu B, Fan HJ, Chen HM, Huang GQ, Liu M, et al. Ginsenoside Ro, an oleanolic saponin of Panax ginseng, exerts antiinflammatory effect by direct inhibiting toll like receptor 4 signaling pathway. J Ginseng Res 2022;46:156-66. https://doi.org/10.1016/j.jgr.2021.05.011
  36. Cho YK, Kim JE, Lee SH, Foley BT, Choi BS. Impact of HIV-1 subtype and Korean Red Ginseng on AIDS progression: comparison of subtype B and subtype D. J Ginseng Res 2019;43:312-8. https://doi.org/10.1016/j.jgr.2018.07.006
  37. Gupta S, Neogi U, Srinivasa H, Shet A. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings. J Antimicrob Chemother 2013;68:2003-6. https://doi.org/10.1093/jac/dkt138
  38. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77: 13376-88. https://doi.org/10.1128/JVI.77.24.13376-13388.2003